OncoMatch/Clinical Trials/NCT06903377

Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer

Is NCT06903377 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ZG005 for and Gecacitinib Hydrochloride Tablets for non-small cell lung cancer.

Phase 1/2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT06903377Data as of May 2026

Treatment: ZG005 for · Gecacitinib Hydrochloride Tablets — This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as the preliminary efficacy of this combination regimen.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify